Effects of fenofibrate on lipid parameters in obese rhesus monkeys

Journal of Lipid Research

Volumn 42, Issue 10, 2001, Pages 1543-1551

  Winegar, Deborah A ^a   Brown, Peter J ^a   Wilkison, William O ^a,c   Lewis, Michael C ^a   Ott, Ronda J ^a   Tong, W Q ^a   Brown, H Roger ^a   Lehmann, Jurgen M ^a,d   Kliewer, Steven A ^a   Plunket, Kelli D ^a   Way, James M ^a   Bodkin, Noni L ^b   Hansen, Barbara C ^b  

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c Zen Bio Inc   (United States)

^d AMGEN INC   (United States)

Author keywords

Apolipoprotein C III; Fibrate; HDL C; PPAR ; Triglyceride lowering

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEINS; BASE SEQUENCE; BLOOD GLUCOSE; BLOTTING, WESTERN; BODY WEIGHT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HYPERLIPIDEMIAS; INSULIN; LIPID METABOLISM; LIPIDS; MACACA MULATTA; MALE; MOLECULAR SEQUENCE DATA; OBESITY; PROCETOFEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS; TRIGLYCERIDES;

EID: 0034753632     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Consensus for the use of fibrates in the treatment of dyslipoporteinemia and coronary heart disease
2. Role of fibrates in the management of hypertriglyceridemia
3. Mechanism of action of fibrates
4. Mode of action of fibrates
5. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene
6. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase: A potential mechanism for the hypolipidemic action of fibrates
7. Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III
8. Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II, and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids
9. Regulation of apo A-1 gene expression by fibrates
10. Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans
11. Biochemical mechanisms of induction of hepatic peroxisome proliferators: Biological implications
12. The PPARs: From orphan receptors to drug discovery
13. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
14. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat
15. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators
16. Peroxisome proliferator activated receptor-α expression in human liver
17. Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific mAbs
18. Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years
19. Species differences in ciprofibrate induction of hepatic cytochrome P450 4AI and peroxisome proliferation
20. The effect of beclobric acid and clofibric acid on peroxisomal b-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes
21. Fenofibrate: Metabolism and species differences for peroxisome proliferation in cultured hepatocytes
22. Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients
23. Hepatic peroxisome proliferation in rodents and its significance for humans
24. The hypolipidemic effect of gemfibrozil (CI-719) in laboratory animals
25. Protective effect of ileal bypass versus administration of clofibrate on experimental hypercholesterolemia and atherosclerosis in monkeys
26. Gemfibrozil significantly lowers cynomolgus monkey plasma lipoprotein[a]-protein and liver apolipoprotein[a] mRNA levels
27. Atherosclerosis research in cynomolgus monkeys (Macaca fascicularis)
28. Long-term induction and regression of diet-induced atherosclerotic lesions in rhesus monkeys
29. Atherogenesis during low level hypercholesterolemia in the nonhuman primate
30. The mystery of diabetes and atherosclerosis: Time for a new plot
31. Diabetic dyslipidemia
32. Fibrates, dyslipoproteinaemia and cardiovascular disease
33. Changes in lipoprotein concentrations during the development of noninsulin-dependent diabetes mellitus in obese rhesus monkeys
34. Prospective study of the development of diabetes in spontaneously obese rhesus monkeys
35. Sequential changes in hepatic glucose production and insulin sensitivity during the development of noninsulin-dependent diabetes mellitus in monkeys
36. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARα agonist with potent lipid-lowering activity
37. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
38. Micronised fenofibrate: A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia
39. 2 levels in rhesus monkeys (Macaca mulatta)
40. PPARα activators improve insulin sensitivity and reduce adiposity
41. Improved insulin sensitivity by bezafibrate in rats: Relationship to fatty acid composition of skeletal-muscle triglycerides
42. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance
43. Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients
44. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight
45. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats
46. Hypertriglyceridemia as a cardiovascular risk factor
47. Serum triglycerides and clinical benefit in lipid-lowering trials
48. Triglyceride-rich lipoproteins and progression of atherosclerosis
49. Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones
50. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
51. Mechanisms and clinical effects of thiazolidinediones